Best Oncology Companies in Rockville, United States
The 35 best Oncology companies in Rockville, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Arcellx.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Rockville
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Arcellx Developer of T cell-mediated anti tumour therapy | $200M | 43 mo ago | 130 130 → 224 (+72%) | David Hilbert Founder & Co-CEO | Acquired | 151 patents Engineered binding domains and multifunctional immune cell therapies for targeted protein therapeutics | — |
| 2 | Clasp Therapeutics Developer of T cell therapeutics for the treatment of cancer | $150M | 30 mo ago | — | Shibin Zhou Co-Founder | Series A | — | — |
| 3 | MacroGenics Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease | $126M | 90 mo ago | 339 339 → 378 (+12%) | Scott Koenig President and CEO | Public | 1,736 patents Therapeutic antibodies and ADCs targeting immune checkpoints (PD‑1, ADAM9, B7‑H3) for cancer. | — |
| 4 | Immunomic Therapeutics Vaccines for allergy, cancer and infectious disease. 57Funding top 24%Growth top 28%Product top 30%Innovation top 34% All 9 signals ▾Fundingtop 24% Growthtop 28% Producttop 30% Innovationtop 34% Moattop 39% Techbottom 44% Marketbottom 37% Globalbottom 37% Newsbottom 21% Funding: Raised $97.9M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) Growth: Headcount 38 → 51 (+34%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $98M | 15 mo ago | 51 | — | Series B | — | — |
| 5 | CASI Pharmaceuticals Developer of therapeutics for the treatment of cancer 60Product top 19%Funding top 26%Growth top 36%Innovation top 38% All 10 signals ▾Producttop 19% Fundingtop 26% Growthtop 36% Innovationtop 38% Fin. healthtop 43% Markettop 46% Moatbottom 49% Globalbottom 44% Newsbottom 41% Techbottom 33% Product: 3 distinct product lines · Company stage: Public Funding: Raised $69.5M across 5 rounds · 5 rounds over 20 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $69M | 8 mo ago | 234 | — | Public | — | — |
| 6 | American Gene Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases 55Funding top 24%Patents top 31%Moat top 35%Talent top 35% All 11 signals ▾Fundingtop 24% Patentstop 31% Moattop 35% Talenttop 35% Innovationtop 37% Growthtop 40% Producttop 40% Techtop 46% Marketbottom 36% Globalbottom 36% Newsbottom 22% Funding: Raised $52.8M across 10 rounds · 10 rounds over 13 yrs (0.8/yr) Patents: 228 patents matched (strict assignee match) · 90 filings since 2022 vs 138 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $53M | 10 mo ago | 31 | Jeff Galvin Chief Executive Officer | Series B | 228 patents Non-integrating viral gene delivery and gamma‑delta T‑cell immunotherapy for HIV and cancer | — |
| 7 | OncoC4 Developer of immunotherapy for cancer patients 62Patents top 17%Innovation top 21%Funding top 28%Moat top 33% All 7 signals ▾Patentstop 17% Innovationtop 21% Fundingtop 28% Moattop 33% Globalbottom 43% Marketbottom 42% Newsbottom 34% Patents: 128 patents matched (strict assignee match) · 115 filings since 2022 vs 13 in 2017-21 Innovation: 128 patents (top 15% of patent-holders) · 115 filings since 2022 vs 13 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $52M | 11 mo ago | 41 | — | Series B | 128 patents Patents concentrated in chemistry & materials | 1 job opening |
| 8 | Cytimmune Multifunctional and tumor-targeted cancer therapies | $15M | 68 mo ago | 1 | Lawrence Tamarkin Co-Founder | Early Stage | — | — |
| 9 | Benevir Innovative medicine, therapies, and medical technology for global healthcare solutions | $11M | 106 mo ago | 10 | — | Acquired | — | — |
| 10 | BioMarker Strategies Develops Cancer Diagnostics System | $7M | 108 mo ago | 8 | Jerry Parrott President | Series A | 42 patents Predictive biomarkers and methods to overcome resistance in cancer immunotherapy. | — |
| 11 | Theranostics Health Personalized medicine through proteomic-based diagnostics and therapeutics for improved healthcare | $7M | 132 mo ago | 5 | Luis Gutierrez President & CEO | Acqui-Hired | — | — |
| 12 | Brain Biosciences Secure Google Account access, management, and language localization services | $6M | 132 mo ago | 4 | David Beylin CEO | Funding Raised | — | — |
| 13 | miRecule Developing microRNA therapies for the treatment of cancers | $5M | 12 mo ago | 8 | Anthony Saleh Co-Founder & CEO | Seed | 52 patents Muscle‑targeted imaging agents and oligonucleotide therapeutics for neuromuscular diseases | — |
| 14 | Creatv Bio Developer of blood based tests for treating cancer | $4M | 84 mo ago | 9 | — | Funding Raised | — | — |
| 15 | KinaRx Developer of novel kinase inhibitors to treat cancer | $2M | 75 mo ago | — | Herman Sintim Co-Founder | Funding Raised | — | — |
| 16 | Aparna Biosciences Developer of biomedical nanoparticle technology and products for research and treatment of human disease | $2M | 204 mo ago | — | Puthupparampil Scaria Co-Founder | Funding Raised | — | — |
| 17 | Shuttle Pharma Developer of therapies to improve outcome of radiation therapy in cancer suffering patients | $1M | 15 mo ago | 7 | — | Public | — | — |
| 18 | HepC Developer of antiviral biologic products | $400K | — | — | Thomas Bakacs CEO | Funding Raised | — | — |
| 19 | Paradigm Shift Therapeutics E-commerce platform accelerating progress in Southeast Asia through commerce and technology | $350K | 120 mo ago | 4 | Kate Farrell Co-Founder & CEO | Funding Raised | — | — |
| 20 | Ariadne Diagnostics Developer of diagnostic tests for oncology and neurodegenerative diseases | $100K | 158 mo ago | 5 | Ilya Mazo Co-Founder & CEO | Seed | — | — |
Top 12 Oncology companies in Rockville
#1
Public · Rockville, Maryland · founded 1991 · 234 employees$69.5Mraised▾
Developer of therapeutics for the treatment of cancer. The company's pipeline includes ENMD-2076, a selective angiogenic kinase inhibitor, and 2ME2 for autoimmune disorders. ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia and hepatocellular carcinoma.
- Dec 2025Post IPO$5M
- Jun 2024Post IPO$15M
- Jan 2016Post IPO$10.3M
- Feb 2012Post IPO$10M
#2
Series B · Rockville, Maryland · founded 2008 · 31 employees$52.8Mraised▾
Developer of lentivirus therapies for the treatment of cancer and other chronic human diseases. The company has developed drugs using its delivery platform. The product pipeline includes a liver cancer therapeutic lentivirus and an AIDS therapeutic lentivirus, as well as Parkinson’s disease therapeutic lentivirus, and a familial dysautonomia therapeutic lentivirus.
- Nov 2025Series B$310K
- Apr 2022Series B$50M
- Nov 2015Series A$1.2M
- Sep 2015Grant (prize money)$232.2K
#3
Series B · Rockville, Maryland · founded 2020 · 41 employees$52.3Mraised▾
Developer of immunotherapy for cancer patients. The lead product, CD24Fc reduces disease progression to death or respiratory failure. The lead candidate ONC-392 is a next-generation anti-CTLA-4 antibody, other candidates targeting cancer cells through chimeric antigen receptors T cells, bi-specific antibodies, and antibody-drug conjugates cells.
- Oct 2025Series B$50M
- Apr 2020Grant (prize money)$2.3M
#4
Series B · Rockville, Maryland · founded 2005 · 51 employees$97.9Mraised▾
Immunomic Therapeutics develops lysosomal-associated membrane protein-based vaccines for the treatment of allergy and cancer. The company has partnered with Astellas to develop vaccines for Japnese red cedar (Phase 1), peanut allergy (Phase 1). Its immunology pipeline includes AST-VAC1 to treat acute myeloid leukemia (AML) (Phase 2); LAMP-Vax + pp64 DC therapy for brain cancer (Phase 1); ATTAC-II clinical trial (Phase II), etc.
- May 2025Series B$6.5M
- Jan 2024Series B$3M
- Jan 2021Series B$77.7M
- Jul 2018Series A$314.5K
#5
Seed · Rockville, Maryland · founded 2018 · 8 employees$5.5Mraised▾
Developing microRNA therapies for the treatment of cancers. The company's DREAmiR platform utilizes genomic data of patients to identify and develop disease-targeting therapeutics. The product pipeline includes MC-DX4 for Facioscapulohumeral Muscular Dystrophy (FSHD), and MC-30 for Head & Neck Squamous Cell Carcinoma (HNSCC)
- Sep 2025Grant (prize money)$3.1M
- Apr 2025Grant (prize money)$3.1M
- Sep 2024Grant (prize money)$863.7K
- Sep 2021Grant (prize money)$1.9M
#6
Series A · Rockville, Maryland · founded 2020$150Mraised▾
Developer of T cell therapeutics for the treatment of cancer. The company is developing next-generation T cell engagers that target tumor-specific oncogenic driver mutations across hard-to-treat cancers.
- Mar 2024Series A$150M
- Oct 2023Seed—
#7
Public · Rockville, Maryland · founded 2012 · 7 employees$1Mraised▾
Developer of therapies to improve outcome of radiation therapy in cancer suffering patients. It offers a lead drug candidate Ropidoxuridine which is an orally available halogenated pyrimidine with strong cancer radiation sensitizing properties. It also offers theranostic tools which includes a pretreatment blood test PC‑Rad for prostate cancer RT outcome prediction and a PSMA-targeted ligand for detecting/treating metastatic prostate cancer.
- Jun 2025Post IPO$4.2M
- Oct 2024Post IPO$790K
- Jan 2023Post IPO$4M
- Jan 2019Seed$912.5K
#8
Acquired · Rockville, Maryland · founded 2014 · 130 employees$200Mraised▾
Developer of T cell-mediated anti-tumour therapy. The company has developed its proprietary technology ARC-sparX platform used for the treatment of cancer and autoimmune disease. The ARC-T cells are engineered T-cells that bind to sparX proteins and helps to kill diseased cells. The company's products include CART-ddBCMA and ACLX-001 for multiple myeloma and ACLX-002 for AML. It is also developing therapeutics for solid tumours.
- Jan 2023Post IPO$100M
- Feb 2022Post IPO$10M
- Mar 2021Series C$120M
- Oct 2019Series B$85M
#9
Public · Rockville, Maryland · founded 2000 · 339 employees$126Mraised▾
Developer of novel biologics for the treatment of autoimmune disorders, cancer, and infectious disease. The company is developing immune-based products, including monoclonal antibodies and vaccines to prevent infections in healthy individuals. The company’s Fc engineering technology enables to the improvement of antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. Its lead candidate for cancer is Margetuximab, which is an Fc-optimized monoclonal antibody that targets the human epidermal growth factor receptor 2, or HER2. HER2 is expressed by tumor cells in the breast, gastroesophageal, bladder, and other forms of solid tumor cancers, making it a key marker for biologic therapy.
- Mar 2019Post IPO—
- Jan 2011Series D$12M
- Jul 2010Grant (prize money)$9.8M
- Jun 2010Grant (prize money)$4.7M
#10
Early Stage · Rockville, Maryland · founded 1988 · 1 employees$15Mraised▾
CytImmune Sciences is a clinical stage nanomedicine company which discovers, develops and commercializes multifunctional, tumor-targeted cancer therapies. Using the unique properties of gold nanoparticles, cytotoxic agents, and biology of tumors, the company is developing a pipeline of its proprietory, Aurimune platform-based products binding potent anti-cancer agents, whose toxicity profiles currently prevent or severely limit clinical use to its patented colloidal gold tumor-targeting nanotechnology. The company has more than 60 issued and pending patents for its colloidal gold nanotechnology and 11 issued and pending patents for its monoclonal antibody (mAb) technology in the US, EU, Japan and Canada.
- Dec 2020Conventional Debt—
- Dec 2020Unattributed$997.8K
- Apr 2020Unattributed$50K
- Mar 2019Unattributed$75K
#11
Acquired · Rockville, Maryland · founded 2011 · 10 employees$11Mraised▾
Innovative medicine, therapies, and medical technology for global healthcare solutions. This organization focuses on pioneering new medicines and medical technologies to transform healthcare globally. Their areas of focus include oncology, immunology, neuroscience, and cardiopulmonary solutions, with a strong emphasis on research and development. They are committed to bringing transformational medical innovation to patients, offering resources, clinical trials, and patient support. They operate with a global reach, tailoring their offerings to various regions and healthcare systems. They are dedicated to improving patient outcomes through rigorous science, unwavering compassion, and a focus on precision medicine, data science, and digital health.
- Nov 2017Series A$2M
- Aug 2016Series A$6M
- Feb 2016Series A$3M
- Sep 2012Grant (prize money)$222.7K
#12
Series A · Rockville, Maryland · founded 2007 · 8 employees$7.3Mraised▾
BioMarker Strategies develops Cancer Diagnostics System. The company has developed SnapPath that is a Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. Its PathMAP functional signaling profiles, created using the SnapPath system, provide a new class of biomarker tests that are highly predictive of individual response for targeted treatments of solid tumors.
- Sep 2017Grant (prize money)$299.3K
- Aug 2016Series A$525K
- Jul 2016Grant (prize money)$2.3M
- Sep 2015Grant (prize money)$2.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in the United States
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 12,968 United States-affiliated papers.
- Harvard University573
- The University of Texas MD Anderson Cancer Center559
- Dana-Farber Cancer Institute413
- Johns Hopkins University356
- Cornell University352
- Tumor microenvironment124→1921
- Immune system80→1464
- Immunotherapy66→1342
- Cancer research197→1345
- Cancer immunotherapy35→714
- Tumor microenvironment212→2712
- Immune system142→2161
- Immunotherapy146→1778
- Cancer research238→1815
- Cancer immunotherapy73→718
- Immunotherapy42→624
- Tumor microenvironment65→585
- Immune system31→529
- Cancer immunotherapy27→298
- Cancer research49→277
Where oncology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing oncology patents in the United States
United States oncology patent filing is accelerating — 2,574 filings from 797 assignees (2016–2025), led by Bristol Myers Squibb, IO Therapeutics, UNIV California; annual filings 108→277.
- Bristol Myers Squibb105
- IO Therapeutics91
- UNIV California88
- DANA Farber Cancer INST87
- Memorial Sloan Kettering Cancer 74
- Baylor College Medicine63
- UNIV Texas61
- Editas Medicine47
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.